Please login to the form below

Not currently logged in
Email:
Password:

IQWiG turns down GSK’s lupus drug Benlysta

German HTA body also declines to back Biogen Idec’s Fampyra in its draft assessments

German HTA body IQWiG

GlaxoSmithKline (GSK) has had its lupus treatment Benlysta (belimumab) turned down for use within the national healthcare system in Germany by the Institute for Quality and Efficiency in Health Care (IQWiG).

In a draft assessment the Institute said it was unable to determine if the drug offered additional benefits over current standard therapy, such as steroids and immunosuppressants, for systemic lupus erythematosus (SLE) as GSK had not provided comparison data.

In a statement, GSK said: "This is completely inexplicable from a medical point of view and disregards genuine progress in therapy.

"This may have dire consequences with respect to the often postulated ground-breaking innovations as it is the case for SLE to which no specific pathogenesis-interfering therapy or any licensed therapy has been found yet, even though the need for medical treatment is urgently required."

The UK-based pharma company's comments follow recent criticisms of the German drug approval system by Boehringer Ingelheim's chairman Andreas Barner, who said changes were needed after Boehringer failed to agree a price for its diabetes drug Trajenta (linagliptin), which it has yet to launch in the country.

It is the second major blow for GSK's Benlysta in recent weeks after the UK's National Institute for Health and Clinical Excellence (NICE) said the drug should not be available for routine NHS use in England as there was not enough evidence to indicate it was a cost-effective use of resources.

Benlysta was discovered by Human Genome Sciences, with GSK partnering with the US company to develop and market the drug. It has since been at the heart of ongoing talks between the two companies regarding a possible takeover by GSK.

Further no from IGWiG for Biogen Idec's Fampyra
In addition to its Benlysta guidance, IQWiG also released a draft assessment giving a negative appraisal of Biogen Idec's multiple sclerosis drug Fampyra (prolonged-release fampridine).

The body said the drug provided no additional benefit over physiotherapy in MS patients with walking disability, and that Biogen submitted data that only indirectly compared the two treatments.

Both GSK and Biogen have until May 23 to respond to the assessments, before the German Federal Joint Committee (G-BA) reviews IQWiG's recommendations and issues final guidance.

GSK said it will "analyse the Federal Joint Committee's argumentation thoroughly and will take appropriate action in the ongoing value assessment".

  • Learn more about Germany's AMNOG system of drug approval in our webinar

4th May 2012

Share

Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kantar Health

Kantar Health is a leading global healthcare consulting firm and trusted advisor to many of the world’s leading pharmaceutical, biotech,...

Latest intelligence

Free White Paper: Customer Experience for Pharma
To learn why an effective customer experience strategy is vital for pharma, download our white paper “Customer experience for pharma” to learn more....
How ethical is your brand plan? Introducing the hEQ.
Assess your brand plan’s Healthcare Ethics Quotient and see how these questions can give your brand plan a new perspective and engage your internal teams and external customers....
solution_options.png
Why e-detailing must give options to healthcare professionals
We know, we know. You want to talk about your treatment right away, but this really is an essential step that will make your e-detailing even more credible....